Neurobiology of Aging
Volume 31, Issue 5 , Pages 796-804 , May 2010

Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice

  • Abdelmojib Al-Wandi

      Affiliations

    • School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3US, United Kingdom
    • ,
  • Natalia Ninkina

      Affiliations

    • School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3US, United Kingdom
    • Institute of Physiologically Active Compounds, Russian Academy of Sciences, 1 Severnyj Proezd, Chernogolovka, Russian Federation
    • ,
  • Steven Millership

      Affiliations

    • School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3US, United Kingdom
    • ,
  • Sally J.M. Williamson

      Affiliations

    • Astellas CNS Research Institute, University of Edinburgh, The Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, United Kingdom
    • ,
  • Paul A. Jones

      Affiliations

    • Astellas CNS Research Institute, University of Edinburgh, The Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, United Kingdom
    • Present address: GE Healthcare, R & D, The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL, United Kingdom.
    • ,
  • Vladimir L. Buchman

      Affiliations

    • School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3US, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 29 20879068; fax: +44 29 20874116.

Received 21 April 2008 ,Revised 19 October 2008 ,Accepted 8 November 2008.

References 

  1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239–252
  2. Abercrombie M. Estimation of nicear population from microtome sections. Anat. Rec. 1946;94:239–247
  3. Altar CA, Marien MR, Marshall JF. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 1987;48:390–399
  4. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Hoglinger GU, et al. Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol. 2008;210:182–193
  5. Benno RH, Tucker LW, Joh TH, Reis DJ. Quantitative immunocytochemistry of tyrosine hydroxylase in rat brain. I. Development of a computer assisted method using the peroxidase-antiperoxidase technique. Brain Res. 1982;246:225–236
  6. Buchman VL, Hunter HJ, Pinon LG, Thompson J, Privalova EM, Ninkina NN, et al. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J. Neurosci. 1998;18:9335–9341
  7. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002;22:8797–8807
  8. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl. Acad. Sci. USA. 2004;101:14966–14971
  9. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123:383–396
  10. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson’s disease?. Neurobiol. Dis. 2007;25:134–149
  11. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40:427–446
  12. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell C, et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 2007;26:56–65
  13. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292–1295
  14. da Costa CA, Masliah E, Checler F. Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson’s disease. J. Biol. Chem. 2003;278:37330–37335
  15. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA. 2002;99:14524–14529
  16. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology. 2003;45:14–44
  17. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology. 2004;25:761–769
  18. Fan Y, Limprasert P, Murray IV, Smith AC, Lee VM, Trojanowski JQ, et al. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum. Mol. Genet. 2006;15:3002–3011
  19. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA. 2005;102:3413–3418
  20. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch. Neurol. 2001;58:186–190
  21. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 2002;277:48984–48992
  22. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 2001;32:213–223
  23. Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, Crews L, et al. Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson’s disease. J. Biol. Chem. 2004;279:23622–23629
  24. Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology. 1985;24:19–23
  25. Hokfelt T, Martensson R, Bjorklund A, Kleinau S, Goldstein M. In:  Bjorklund A,  Hokfelt T editor. Handbook of Chemical Neuroanatomy. vol. 2:Amsterdam: Elsevier; 1984;p. 277–379
  26. Kuhn M, Haebig K, Bonin M, Ninkina N, Buchman VL, Poths S, et al. Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics. 2007;8:71–81
  27. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 2004;24:1888–1896
  28. Li JY, Henning Jensen P, Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience. 2002;113:463–478
  29. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 1998;51:890–892
  30. Nakajo S, Shioda S, Nakai Y, Nakaya K. Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Mol. Brain. Res. 1994;27:81–86
  31. Ninkina N, Papachroni K, Robertson DC, Schmidt O, Delaney L, O’Neill F, et al. Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol. Cell. Biol. 2003;23:8233–8245
  32. Papachroni K, Ninkina N, Wanless J, Kalofoutis AT, Gnuchev NV, Buchman VL. Peripheral sensory neurons survive in the absence of alpha- and gamma-synucleins. J. Mol. Neurosci. 2005;25:157–164
  33. Park JY, Lansbury PT. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson’s disease. Biochemistry. 2003;42:3696–3700
  34. Phinney AL, Andringa G, Bol JG, Wolters E, van Muiswinkel FL, van Dam AM, et al. Enhanced sensitivity of dopaminergic neurons to rotenoneinduced toxicity with aging. Parkinsonism Relat. Disord. 2006;12:228–238
  35. Pifl C, Hornykiewicz O. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem. Int. 2006;49:519–524
  36. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047
  37. Rideout HJ, Lang-Rollin I, Stefanis L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int. J. Biochem. Cell Biol. 2004;36:2551–2562
  38. Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J. Neurochem. 2004;89:1126–1136
  39. Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci. Lett. 1989;101:305–310
  40. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL. Induction of neuronal death by alpha-synuclein. Eur. J. Neurosci. 2000;12:3073–3077
  41. Schluter OM, Fornai F, Alessandri MG, Takamori S, Geppert M, Jahn R, et al. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience. 2003;118:985–1002
  42. Shibayama-Imazu T, Okahashi I, Omata K, Nakajo S, Ochiai H, Nakai Y, et al. Cell and tissue distribution and developmental change of neuron specific 14kDa protein (phosphoneuroprotein 14). Brain Res. 1993;622:17–25
  43. Specht CG, Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2001;2:11
  44. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N.Y. Acad. Sci. 2000;920:16–27
  45. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840
  46. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. Cell Death Differ. 1998;5:832–837
  47. Volles MJ, Lansbury PT. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 2002;41:4595–4602
  48. Volles MJ, Lansbury PT. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry. 2003;42:7871–7878
  49. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry. 2001;40:7812–7819
  50. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003;278:25009–25013

☆ All animal work was carried in accordance with the United Kingdom Animals (Scientific Procedures) Act (1986).

PII: S0197-4580(08)00397-7

doi: 10.1016/j.neurobiolaging.2008.11.001

Neurobiology of Aging
Volume 31, Issue 5 , Pages 796-804 , May 2010

Article Tools

* Image Usage & Resolution